text stringlengths 1 5.46k |
|---|
Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101 |
- Alpine grants AbbVie option to license worldwide rights to ALPN-101, a phase 2-ready, first-in-class dual CD28/ICOS costimulation antagonist, building on AbbVie's commitment to developing novel therapies in Immunology |
- Alpine to receive $60 million in an upfront cash payment; eligible to receive up to $805 million for exercise of the option and success-based development, regulatory and commercial milestones |
- Alpine to conduct a phase 2 study in systemic lupus erythematosus during the option period |
- Alpine will host a conference call today at 8:30 a.m. ET - |
SEATTLE, WA and NORTH CHICAGO, Ill., June 18, 2020 -- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, and AbbVie Inc. (NYSE: ABBV), a research-based global biopharmaceutical company, ... |
CD28 and ICOS are key costimulatory molecules that likely play critical roles in multiple autoimmune and inflammatory diseases. ALPN-101 is a potent inhibitor of both CD28 and ICOS pathways with demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone. Favorable safety ... |
"We are very pleased to partner ALPN-101 with AbbVie, a world leader in the development and commercialization of innovative immunology therapies," said Mitchell H. Gold, M.D., Executive Chairman and Chief Executive Officer of Alpine. "AbbVie is an ideal partner for ALPN-101, with the therapeutic area expertise, R&D com... |
"AbbVie's expertise in Immunology has led to remarkable breakthroughs in the treatment of autoimmune diseases," said Tom Hudson, M.D., Senior Vice President and Chief Scientific Officer, AbbVie. "ALPN-101's dual mechanism of action has compelling potential as a next-generation treatment in systemic lupus erythematosus ... |
Under the terms of the agreement, Alpine will receive an upfront payment of $60 million, and will also be eligible to receive up to an aggregate of $805 million for exercise of the option and success-based development, regulatory and commercial milestones. In addition, Alpine is eligible to receive tiered royalties on ... |
Alpine will host a conference call today at 8:30 a.m. ET to discuss the option and license agreement and outline the company's strategic focus moving forward. |
Conference Call and Webcast Details |
Alpine will host a conference call today at 8:30 a.m. ET to discuss today's announcement. To access the live call by phone, dial (800) 816-3005 (domestic) or (857) 770-0069 (international) using participant passcode 3770288. To access a live webcast of the call, please visit the Investor Relations section of the Alpine... |
About Alpine Immune Sciences, Inc. |
Alpine Immune Sciences, Inc. is committed to leading a new wave of immune therapeutics, creating potentially powerful multifunctional immunotherapies to improve patients' lives via unique protein engineering technologies. Alpine is backed by world-class research and development capabilities, a highly productive scienti... |
About AbbVie |
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and... |
Forward-Looking Statements |
Alpine Immune Sciences, Inc.: |
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regardin... |
AbbVie: |
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe,""expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions tha... |
Contacts |
Alpine Immune Sciences, Inc.: |
Media |
Jennifer Paganelli, W20 |
212-301-7225 |
jpaganelli@w2ogroup.com |
Investors: |
Laurence Watts, Gilmartin Group, LLC.: |
619-916-7620 |
laurence@gilmartinir.com |
AbbVie |
Media: |
Adelle Infante |
847-938-8745 |
adelle.infante@abbvie.com |
Investors: |
Liz Shea |
847-935-2211 |
liz.shea@abbvie.com |
Source: Alpine Immune Sciences Inc.; AbbVie Inc. |
Schedule 10.2 |
Licensor Disclosure Schedule |
Section 10.2.2 The Identified Patent described in Schedule 6.6.3(c) (Special Offset). |
Schedule 10.2.1 |
Existing Licensor Product Patents |
AIS Family No. 03 Attorney Reference No. 76161.x0003.xx ICOS LIGAND VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF |
Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments |
US 30003.00 62/323,608 (4/15/2016) None Expired |
US 30003.01 62/394,745 (9/14/2016) None Expired |
US 30003.02 62/410,842 (10/20/2016) None Expired |
US 30003.03 62/472,568 (3/16/2017) None Expired |
US 30003.04 62/475,162 (3/22/2017) None Expired |
PCT 20003.40 PCT/US2017/027811 (4/14/2017) WO 2017/181148 (10/19/2017) Expired; Nat'l phase filed |
AU 20003.41 2017250358 (9/26/2018) AU-A-2017250358 (10/18/2018) Pending |
BR 20003.42 BR 11 2018 070934 4 (10/10/2018) BR1120180709344 (2/26/2019) Pending |
CA 20003.43 3,019,199 (9/26/2018) CA 3019199 (10/04/2018) Pending |
CN 20003.44 201780036984.0 (12/13/2018) CN 110088126 (08/02/2019) Pending |
EA 20003.45 201892336 (11/14/2018) EA 201892336 (06/28/2019) Pending |
EP 20003.46 17733114.7 (9/28/2018) EP 3442999 (02/20/2019) Pending |
IL 20003.47 262365 (10/14/2018) IL 262365 (11/29/2018) Pending |
IN 20003.48 201817041129 (10/31/2018) IN 201817041129 (03/01/2019) Pending |
JP 20003.49 2018-554101 (12/10/2018) JP 2019514361 (06/06/2019) Pending |
KR 20003.50 10-2018-7033049 (11/14/2018) KR 20190005879 (01/16/2019) Pending |
MX 20003.51 MX/a/2018/012472 (10/11/2018) MX/a/2018/012472 (09/06/2019) Pending |
NZ 20003.52 746741 (9/26/2018) NZ 746741 A1 (09/28/2019) Pending |
SG 20003.53 11201808457P (9/27/2018) SG 11201808457P (10/30/2018) Pending |
HK (EP) 20003.54 19121707.4 (4/1/2019) HK 1261801 (1/3/2020) Pending |
HK (CN) 20003.55 19128847.1 (8/28/2019) Not yet published Pending |
US 20003.00 15/488409 (04/14/2017) US 2017/0320959 (11/9/2017) Pending |
AIS Family No. 07 |
MULTI-DOMAIN IMMUNOMODULATORY PROTEINS AND METHODS OF USE THEREOF Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments |
US 30007.00 62/613,378 (01/03/2018) None Expired |
US 30007.01 62/733,622 (09/19/2018) None Expired |
PCT 20007.40 PCT/US2019/012222 (01/03/2019) WO 2019/136179 (07/11/2019) Pending |
AIS Family No. 12 Attorney Reference No. 76161.x0022.xx VARIANT ICOS LIGAND IMMUNOMODULATORY PROTEINS AND RELATED COMPOSITIONS AND METHODS |
Country Atty. Ref. Application No. (Country Filing Date) Publication No. (Publication Date) Status and Comments |
US 30022.00 62/574,161 (10/18/2017) None Expired |
AR 20022.41 20180103041 (10/18/2018) None Pending |
TW 20022.42 107136610 (10/17/2018) 201925223 (07/01/2019) Pending |
PCT 20022.40 PCT/US2018/056381 (10/17/2018) WO 2019/079520 (04/25/2019) Expired; Nat'l phase filed by 18 April 2020 |
AU 20022.43 2018351000 (4/9/2020) AU-A1-2018351000 (04/30/2020) Pending |
BR 20022.44 BR 11 2020 007542 6 (4/16/2020) Not yet published Pending |
CA 20022.45 3,078,517 (4/3/2020) CA 3078517 A1 (04/25/2019) Pending |
CN 20022.46 Not yet available Not yet published Pending |
EA 20022.47 202090974 (05/15/2020) Not yet published Pending |
EP 20022.48 18803814.5 (4/1/2020) Not yet published Pending |
IL 20022.49 273726 (3/31/2020) Not yet published Pending |
IN 20022.50 20201701941 (05/07/2020) Not yet published Pending |
JP 20022.51 2020-521877(4/17/2020) Not yet published Pending |
KR 20022.52 Not yet available Not yet published Pending |
MX 20022.53 MX/a/2020/004540 (4/30/2020) Not yet published Pending |
NZ 20022.54 763426 (4/9/2020) Not yet published Pending |
SG 20022.55 11202003078V (4/2/2020) Not yet published Pending |
UAE 20022.56 P6000549/20 (4/15/2020) Not yet published Pending |
BH 20022.57 20200069 (4/16/2020) Not yet published Pending |
MY 20022.60 PI2020001960 (4/18/2020) Not yet published Pending |
PH 20022.62 Not yet available Not yet published Pending |
QA 20022.63 QA/202004/00202 (4/15/2020) Not yet published Pending |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.